| [August 12, 2011] |
 |
Research and Markets: Multiple Myeloma Pipeline Review, Q3 2011 - The Latest Pipeline Updates, Products & News for the Multiple Myeloma Therapeutic Industry
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/07d5e7/multiple_myeloma)
has announced the addition of Global Markets Direct's new report "Multiple
Myeloma - Pipeline Review, Q3 2011" to their offering.
Global Markets Direct's, 'Multiple
Myeloma - Pipeline Review, Q3 2011', provides an overview of the
Multiple Myeloma therapeutic pipeline. This report provides information
on the therapeutic development for Multiple Myeloma, complete with
latest updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic
development for Multiple Myeloma.
'Multiple
Myeloma - Pipeline Review, Q3 2011' is built using data and
information sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC (News - Alert) filings, investor presentations and
featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets
Direct's team.
Note: Certain sections in the report may be removed or altered based on
the availability and relevance of data for the indicated disease.
Scope:
-
A snapshot of the global therapeutic scenario for Multiple Myeloma.
-
A review of the Multiple Myeloma products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources.
-
Coverage of products based on various stages of development ranging
from discovery till registration stages.
-
A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
-
Coverage of the Multiple Myeloma pipeline on the basis of therapeutic
class, route of administration and molecule type.
-
Profiles of late-stage pipeline products featuring sections on product
description, mechanism of action and research & development progress.
-
Key discontinued pipeline projects.
-
Latest news and deals relating to the products.
Reasons to Buy:
-
Identify and understand important and diverse types of therapeutics
under development for Multiple Myeloma.
-
Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.
-
Plan mergers and acquisitions effectively by identifying players with
the most promising pipeline.
-
Devise corrective measures for pipeline projects by understanding
Multiple Myeloma pipeline depth and focus of Multiple Myeloma
therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/07d5e7/multiple_myeloma
[ Back To TMCnet.com's Homepage ]
|
